ArchPoint Investors’s Teva Pharmaceuticals TEVA Stock Holding History

ArchPoint Investors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,000	Closed	-$88K	–	160
2017 Q3	$88K	Hold	5,000	–	–	0.03%	114
2017 Q2	$166K	Hold	5,000	–	–	0.05%	101
2017 Q1	$160K	Buy	+5,000	New	+$171K	0.06%	86
2016 Q4	–	Sell	-5,000	Closed	-$230K	–	94
2016 Q3	$230K	Hold	5,000	–	–	0.13%	79
2016 Q2	$251K	Buy	+5,000	New	+$266K	0.14%	76

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

ArchPoint Investors's TEVA Position: Q4 2017 in Review

ArchPoint Investors sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 5,000 shares — an estimated $88K sold.

ArchPoint Investors first reported a position in TEVA in Q2 2016 and held it in 5 quarters. The position peaked at $251K in Q2 2016. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

ArchPoint Investors reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
ArchPoint Investors sold 5,000 Teva Pharmaceuticals shares in Q4 2017, an estimated $88K.
ArchPoint Investors first reported a position in Teva Pharmaceuticals in Q2 2016 and held it in 5 quarters.
ArchPoint Investors's Teva Pharmaceuticals position peaked at $251K in Q2 2016.
507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on ArchPoint Investors's 13F filing for Q4 2017, filed 14 Feb 2018.